Company: CMND
Filing Date: 2025-11-26
Form Type: 424B5
Source: 0001213900-25-115106
Chunk: 39

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: 424B5
Chunk 39
---
,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

| ● | the                                                                                                                                 
 ability of our pre-clinical and any future clinical trials to demonstrate safety and efficacy of our future product candidates, and 
 other positive results;                                                                                                             |

| ● | the                                                                                                                              
 timing and focus of our future preclinical studies and clinical trials, and the reporting of data from those studies and trials; |

| ● | the                                                                                                                                 
 size of the market opportunity for our future product candidates, including our estimates of the number of patients who suffer from 
 the diseases we are targeting;                                                                                                      |

| ● | the                                                              
 success of competing therapies that are or may become available; |

| ● | the                                                                                                                                        
 beneficial characteristics, safety, efficacy and therapeutic effects of our future product candidates, as well as the potential healthcare 
 costs saved through utilizing our future product candidates;                                                                               |

| ● | the                                                                                                           
 ability of our future product candidate to address needs not currently addressed by the psychedelic industry; |

| ● | our                                                                                  
 ability to obtain and maintain regulatory approval of our future product candidates; |

| ● | our                                                                                                                               
 plans relating to the further development of our future product candidates, including additional disease states or indications we 
 may pursue;                                                                                                                       |

| ● | existing                                                                              
 regulations and regulatory developments in the United States and other jurisdictions; |

| ● | our                                                                                                                               
 plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our 
 ability to avoid infringing the intellectual property rights of others;                                                           |

| ● | the                                                                   
 ability of our management team to oversee our drug research programs; |

| ● | the                                                                                     
 need to hire additional personnel and our ability to attract and retain such personnel; |

| ● | our                                                                                                    
 estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |

| ● | our                          
 dependence on third parties; |

| ● | our                                                                                                                                     
 ability to compete with other companies who offer products that address similar issues that our future product candidates will address; |

| ● | our                    
 financial performance; |

<div align='center'>7</div>

| ● | the                                                                                                                               
 period over which we estimate our existing cash and cash